Molecular testing is recommended for various groups of cancer patients:
Patients with advanced or metastatic cancer where standard treatments have failed. Patients with rare or unusual cancers where specific genetic mutations are suspected. Patients eligible for clinical trials involving targeted therapies. Patients with a family history of cancer, where genetic predisposition is a concern.
